Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 9/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.41 |
| ▸ | PNMT | P11086 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12436727 | 0.84 | SIGMAR1 (0.58) | TMEM97SIGMAR1KCNH2PNMTTAAR1 | |
| SCHEMBL18926474 | 0.82 | MMP1 (0.40) | SIGMAR1 | |
| SCHEMBL10019195 | 0.80 | PNMT (0.50) | SIGMAR1PNMTMEN1KMT2APKM | |
| SCHEMBL25823349 | 0.79 | TMEM97 (0.43) | TMEM97SIGMAR1KCNH2PNMTTAAR1 | |
| SCHEMBL12841593 | 0.78 | SKP2 (0.46) | SIGMAR1PNMTTAAR1MEN1KMT2A | |
| SCHEMBL13965846 | 0.78 | CYP1A2 (0.41) | PNMTMEN1KMT2A | |
| SCHEMBL21410551 | 0.77 | SKP2 (0.59) | — | |
| SCHEMBL14752345 | 0.77 | ESR1 (0.59) | SIGMAR1KCNH2MEN1KMT2A | |
| SCHEMBL20974679 | 0.77 | PNMT (0.43) | TMEM97SIGMAR1KCNH2PNMTTAAR1 | |
| SCHEMBL12333663 | 0.76 | ALDH1A1 (0.47) | PNMTTAAR1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-07-18 | — | — | US | disclosed |
| US-20180185306-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2018-07-05 | — | — | US | disclosed |
| US-9861596-B2 | Compositions and methods for treating neurological diseases or injury | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2018-01-09 | — | — | US | disclosed |
| US-20150320702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | CYP2A6, CYP2B6, CYP4A11 | TMEM97 3475/4885SIGMAR1 1833/4885KCNH2 4410/4885 |
| US-20150320702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY | PROC, GLS, NLN | TMEM97 4714/4885SIGMAR1 4860/4885KCNH2 57/4885 |
| US-20180185306-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY | PROC, GLS, NLN | TMEM97 4714/4885SIGMAR1 4860/4885KCNH2 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.